X

Trial Profile

Pilot Study to Assess the Use of JSP191 in Matched Unrelated Donor Transplantation for Chronic Granulomatous Disease (CGD)

Status: Recruiting

Phase of Trial: Phase 0

Latest Information Update: 17 May 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Briquilimab (Primary) ; Alemtuzumab; Cyclophosphamide
Indications Chronic granulomatous disease
Focus Therapeutic Use

Most Recent Events

03 May 2024 According to Jasper Therapeutics media release, data from this trial presented at the 2024 Clinical Immunological Society (CIS) Annual Meeting
04 Jan 2023 Planned initiation date changed from 9 Jan 2023 to 10 Jan 2023.
03 Jan 2023 Planned initiation date changed from 4 Jan 2023 to 9 Jan 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com